ABSTRACT
BACKGROUND Acute kidney injury (AKI) is a common complication in patients suffering from acute coronary syndromes (ACS) and treated by percutaneous coronary intervention (PCI). Contrast media (CM) volume minimization has been advocated to prevent AKI. The DyeVert™ system (Osprey Medical Inc., Minnetonka, MN, USA) is a device designed to reduce CM volume during coronary procedures, while maintaining fluoroscopic image quality.
METHODS In this is study a randomized, single-blind, investigator-driven clinical trial conducted in 4 italian interventional cardiology centers from February 4, 2020 to September 13, 2022, 550 ACS participants were randomly assigned in 1:1 ratio to 1) Control group (n = 274), in which a conventional manual or automatic injection syringe was used, and 2) Contrast Volume Reduction (CVR) group (n = 276), in which CM injection was handled by the DyeVertTM system. The primary endpoints were 1) CM volume, and 2) the rate of AKI, defined as a serum creatinine (sCr) increase ≥0.3 mg/dL within 48 hours after CM exposure.
RESULTS There were 412/550 (74.5%) participants with ST-elevation myocardial infarction (201/274 [73.3%] in the Control group and 211/276 [76.4%] in the CVR group). Mean glomerular filtration rate was 84±32 mL/min/1.73 m2 in the Control group and in 85±34 mL/min/1.73 m2 in the CVR group (p = 0.78). CM volume was higher in the Control group (160 ± 23 mL versus 95 ± 30 mL; p < 0.001). Seven participants (6 in the Control group and one in the CVR group) did not have post-procedural sCr values. AKI occurred in 65/268 (24.3%) participants in the Control group and in 44/275 (16%) participants in the CVR group (RR = 0.66; 95% confidence interval 0.47-0.93; p = 0.018).
CONCLUSIONS CM volume reduction obtained by the DyeVertTM system is effective to prevent AKI in ACS patients undergoing invasive procedure.
Trial Registration The study is registered with www.clinicaltrial.gov (NCT04714736)
What Is New?
Contrast media volume reduction obtained by the DyeVertTM system is effective to prevent acute kidney injury in acute coronary syndrome patients undergoing invasive procedure.
What Are the Clinical Implications?
Contrast media volume minimization is of outmost important in the attempt to prevent acute kidney injury. The DyeVert™ system is an “operator-independent” tool contributing to the contrast media-sparing approach.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04714736
Funding Statement
The study is investigator-driven. The company providing the DyeVert system (Osprey Medical Inc. Minnetonka, MN, USA) was not involved in the trial design and conduction.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Comitato Etico Campania Centro on January 22, 2020. prot. n. 29/ C.E. 24-19
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be available upon appropriate request
